• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013 - Product Image

Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013

  • ID: 2557641
  • May 2013
  • 88 pages
  • Global Markets Direct

Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria. Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated READ MORE >

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Overview
Therapeutics Development
An Overview of Pipeline Products for Skin And Skin Structure Infections (SSSI) Caused By Bacteria
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics under Development by Companies
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics – Products under Development by Companies
Companies Involved in Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics Development
GlaxoSmithKline plc
Rib-X Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc.
Affinium Pharmaceuticals, Inc.
Nabriva Therapeutics AG
Cempra Pharmaceuticals, Inc.
Trius Therapeutics, Inc.
Tetraphase Pharmaceuticals Inc.
Durata Therapeutics Inc.
Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
dalbavancin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GSK-1322322 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFN-1252 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AFN-1252 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
omadacycline tosylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
BC-7013 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
delafloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
radezolid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oritavancin disphosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
fusidic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
tedizolid phosphate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
avarofloxacin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ABI-0043 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
eravacycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Bismith-Thiol Compound For Acute Wound Infection - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics – Drug Profile Updates
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics – Discontinued Products
Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Product Development Milestones
Featured News & Press Releases
Nov 16, 2012: PolyMedix Announces Successful Meeting With FDA For Brilacidin
Oct 25, 2012: Durata Therapeutics Completes Target Enrollment In Phase III Study Comparing Dalbavancin To Vancomycin And Linezolid In ABSSSI Patients
Oct 18, 2012: Durata Therapeutics Presents Results From Skin Lesion Measurement Study Of Dalbavancin At IDWeek 201
Oct 16, 2012: Trius Therapeutics To Present Data From Tedizolid Clinical Studies At IDWeek Conference
Oct 10, 2012: Rib-X Pharma Receives Qualified Infectious Disease Product Designation From FDA For Radezolid
Oct 04, 2012: Durata Therapeutics To Present Two Abstracts Concerning Dalbavancin At IDWeek 201
Sep 11, 2012: Durata Therapeutics Announces Completion Of QT Study Of Dalbavancin
Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 201
Sep 11, 2012: PolyMedix Presents New Data On Defensin-Mimetic Antibiotics At 52nd Annual ICAAC 201
Sep 11, 2012: Rib-X Pharma Presents Data From Multiple Radezolid Studies At ICAAC 201
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H1 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Comparative Analysis, H1 2013
Number of Products under Development by Companies, H1 2013
Comparative Analysis by Late Stage Development, H1 2013
Comparative Analysis by Mid Clinical Stage Development, H1 2013
Comparative Analysis by Early Clinical Stage Development, H1 2013
Comparative Analysis by Pre-Clinical Stage Development, H1 2013
Products under Development by Companies, H1 2013
GlaxoSmithKline plc, H1 2013
Rib-X Pharmaceuticals, Inc., H1 2013
Paratek Pharmaceuticals, Inc., H1 2013
Affinium Pharmaceuticals, Inc., H1 2013
Nabriva Therapeutics AG, H1 2013
Cempra Pharmaceuticals, Inc., H1 2013
Trius Therapeutics, Inc., H1 2013
Tetraphase Pharmaceuticals Inc., H1 2013
Durata Therapeutics Inc., H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Stage and Molecule Type, H1 2013
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics – Drug Profile Updates
Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics – Discontinued Products

List of Figures
Number of Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, H1 2013
Products under Development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria – Comparative Analysis, H1 2013
Products under Development by Companies, H1 2013
Late Stage Products, H1 2013
Mid Clinical Stage Products, H1 2013
Early Clinical Stage Products, H1 2013
Pre-Clinical Stage Products, H1 2013
Assessment by Monotherapy Products, H1 2013
Assessment by Route of Administration, H1 2013
Assessment by Stage and Route of Administration, H1 2013
Assessment by Molecule Type, H1 2013
Assessment by Stage and Molecule Type, H1 2013 30

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos